|Project Title||Principal Investigator||Institution|
|Oxytocin vs placebo on response inhibition & face processing in autism||Anagnostou, Athanasius||Mount Sinai School of Medicine|
|Intransal oxytocin in the treatment of autism||Anagnostou, Athanasius||Mount Sinai School of Medicine|
|Neuronal nicotonic receptor modulation in the treatment of autism: A pilot trial of mecamylamine||Arnold, L. Eugene||The Ohio State University|
|A randomized, double blind, placebo controlled study of fatty acid supplementation in autism||Carpenter, Laura||Medical University of South Carolina|
|Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism||Hendren, Robert||University of California, Davis|
|Divalproex sodium ER in adult autism||Hollander, Eric||Mount Sinai School of Medicine|
|Understanding repetitive behavior in autism||McCracken, James||University of California, Los Angeles|
|Aripiprazole in children and adolescents with autistic disorder||McDougle, Christopher||Indiana University-Purdue University Indianapolis|
|Risperidone and behavior therapy in children and adolescents with pervasive disorder||McDougle, Christopher||Indiana University-Purdue University Indianapolis|
|The pharmacognetics of treatment for insistence sameness in autism||Owley, Thomas||University of Illinois at Chicago|
|D-cycloserine in children and adolescents with autism||Posey, David||Indiana University-Purdue University Indianapolis|
|Double masked placebo controlled trial of cholesterol in hypocholesterolemic ASD||Tierney, Elaine||Kennedy Krieger Institute|
|IACC Strategic Plan Objectives||2008||2009||2010||2011||2012||Total|
|Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014.
IACC Recommended Budget: $22,200,000 over 5 years
|4.L.A. Funding: The recommended budget was partially met.
Progress: 10-14 studies have been funded, which is more than the minimum recommended, and momentum within the pre-clinical phases of this objective is currently building. It should be noted, however, in that many of these studies are small trials or pilot studies.Â
Remaining Gaps, Needs, and Opportunities: Though there is little evidence that CNS drug development in animals will translate to humans, either in terms of toxicity or efficacy, there is still a need for investment in well-established animal model studies to identify promising molecular, cellular, or systems targets before mounting randomized clinical trials in humans. However, existing drugs for other indications may be adapted to ASD without extensive pre-clinical work, and there is also evidence for proof of concept studies for ASD (particularly those addressing core symptoms). It is also critically important to develop appropriate outcome measures for use in trials.